View in EDS

Optimization of hERG and Pharmacokinetic Properties for Basic Dihydro-8H-purin-8-one Inhibitors of DNA-PK.

Saved in:
Bibliographic Details
Title: Optimization of hERG and Pharmacokinetic Properties for Basic Dihydro-8H-purin-8-one Inhibitors of DNA-PK.
Authors: Goldberg FW; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Ting AKT; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Beattie D; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Lamont GM; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Fallan C; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Finlay MRV; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Williamson B; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Schimpl M; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Harmer AR; Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Adeyemi OB; Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Nordell P; Biopharmaceuticals R&D, AstraZeneca, 431 50 Gothenburg, Sweden., Cronin AS; Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Vazquez-Chantada M; Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Barratt D; Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Ramos-Montoya A; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Cadogan EB; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K., Davies BR; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.
Source: ACS medicinal chemistry letters [ACS Med Chem Lett] 2022 Jul 07; Vol. 13 (8), pp. 1295-1301. Date of Electronic Publication: 2022 Jul 07 (Print Publication: 2022).
Publication Type: Journal Article
Journal Info: Publisher: American Chemical Society Country of Publication: United States NLM ID: 101521073 Publication Model: eCollection Cited Medium: Print ISSN: 1948-5875 (Print) Linking ISSN: 19485875 NLM ISO Abbreviation: ACS Med Chem Lett Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 35978693
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Optimization of hERG and Pharmacokinetic Properties for Basic Dihydro-8H-purin-8-one Inhibitors of DNA-PK.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Goldberg+FW%22">Goldberg FW</searchLink>; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Ting+AKT%22">Ting AKT</searchLink>; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Beattie+D%22">Beattie D</searchLink>; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Lamont+GM%22">Lamont GM</searchLink>; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Fallan+C%22">Fallan C</searchLink>; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Finlay+MRV%22">Finlay MRV</searchLink>; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Williamson+B%22">Williamson B</searchLink>; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Schimpl+M%22">Schimpl M</searchLink>; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Harmer+AR%22">Harmer AR</searchLink>; Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Adeyemi+OB%22">Adeyemi OB</searchLink>; Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Nordell+P%22">Nordell P</searchLink>; Biopharmaceuticals R&D, AstraZeneca, 431 50 Gothenburg, Sweden.<br /><searchLink fieldCode="AU" term="%22Cronin+AS%22">Cronin AS</searchLink>; Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Vazquez-Chantada+M%22">Vazquez-Chantada M</searchLink>; Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Barratt+D%22">Barratt D</searchLink>; Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Ramos-Montoya+A%22">Ramos-Montoya A</searchLink>; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Cadogan+EB%22">Cadogan EB</searchLink>; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.<br /><searchLink fieldCode="AU" term="%22Davies+BR%22">Davies BR</searchLink>; Oncology R&D, AstraZeneca, Cambridge CB2 0AA, U.K.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101521073%22">ACS medicinal chemistry letters</searchLink> [ACS Med Chem Lett] 2022 Jul 07; Vol. 13 (8), pp. 1295-1301. <i>Date of Electronic Publication: </i>2022 Jul 07 (<i>Print Publication: </i>2022).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Chemical+Society%22">American Chemical Society </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101521073 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>1948-5875 (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2219485875%22">19485875 </searchLink><i>NLM ISO Abbreviation: </i>ACS Med Chem Lett <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=35978693
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1021/acsmedchemlett.2c00172
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1295
    Titles:
      – TitleFull: Optimization of hERG and Pharmacokinetic Properties for Basic Dihydro-8H-purin-8-one Inhibitors of DNA-PK.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Goldberg FW
      – PersonEntity:
          Name:
            NameFull: Ting AKT
      – PersonEntity:
          Name:
            NameFull: Beattie D
      – PersonEntity:
          Name:
            NameFull: Lamont GM
      – PersonEntity:
          Name:
            NameFull: Fallan C
      – PersonEntity:
          Name:
            NameFull: Finlay MRV
      – PersonEntity:
          Name:
            NameFull: Williamson B
      – PersonEntity:
          Name:
            NameFull: Schimpl M
      – PersonEntity:
          Name:
            NameFull: Harmer AR
      – PersonEntity:
          Name:
            NameFull: Adeyemi OB
      – PersonEntity:
          Name:
            NameFull: Nordell P
      – PersonEntity:
          Name:
            NameFull: Cronin AS
      – PersonEntity:
          Name:
            NameFull: Vazquez-Chantada M
      – PersonEntity:
          Name:
            NameFull: Barratt D
      – PersonEntity:
          Name:
            NameFull: Ramos-Montoya A
      – PersonEntity:
          Name:
            NameFull: Cadogan EB
      – PersonEntity:
          Name:
            NameFull: Davies BR
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 07
              M: 07
              Text: 2022 Jul 07
              Type: published
              Y: 2022
          Identifiers:
            – Type: issn-print
              Value: 1948-5875
          Numbering:
            – Type: volume
              Value: 13
            – Type: issue
              Value: 8
          Titles:
            – TitleFull: ACS medicinal chemistry letters
              Type: main
ResultId 1